There is a growing interest in the evaluation of nonmyeloablative conditioning therapy for allogeneic stem cell transplantation. Such regimens are expected to produce less toxicity while allowing both engraftment and a graft-versus-disease effect from the large number of donor-derived immunocompetent T lymphocytes given with the stem cells. Heavy immunosuppression used in recipients may have unexpected consequences. We describe the occurrence of a fatal Epstein-Barr virusassociated B cell lymphoproliferative disease (BLPD) early after such a non-myeloablated allogeneic peripheral blood stem cell transplant in a heavily pretreated patient. Keywords: EBV-associated lymphoproliferative disease; allogeneic transplantation; non-myeloablative regimen According to Slavin et al 1 and Giralt et al 2 the preliminary results achieved following non-myeloablative conditioning regimens for allogeneic stem cell transplantation appear encouraging enough to warrant further studies with a larger number of patients. In these trials, the recipient was profoundly immunosuppressed with a purine analog with or without anti-T lymphocyte globulin (ATG) to allow engraftment of G-CSF-mobilized donor peripheral blood stem cell and a GVL effect mediated by the large number of donor-derived immunocompetent T lymphocytes given with the stem cells. The consequences of such heavy immunosuppression of the recipient are largely unknown but one could speculate that donor T cell immune functions should not be greatly impaired since no additional immunosuppression, apart from cyclosporine, is given post transplant.
According to Slavin et al 1 and Giralt et al 2 the preliminary results achieved following non-myeloablative conditioning regimens for allogeneic stem cell transplantation appear encouraging enough to warrant further studies with a larger number of patients. In these trials, the recipient was profoundly immunosuppressed with a purine analog with or without anti-T lymphocyte globulin (ATG) to allow engraftment of G-CSF-mobilized donor peripheral blood stem cell and a GVL effect mediated by the large number of donor-derived immunocompetent T lymphocytes given with the stem cells. The consequences of such heavy immunosuppression of the recipient are largely unknown but one could speculate that donor T cell immune functions should not be greatly impaired since no additional immunosuppression, apart from cyclosporine, is given post transplant.
Nevertheless, we describe a fatal Epstein-Barr virusassociated B cell lymphoproliferative disease (BLPD) which occurred early after an allogeneic peripheral blood stem cell transplant performed with non-myeloablative conditioning.
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Case report
A 37-year-old patient with common ALL diagnosed 2 years earlier was scheduled for a second transplant using a nonmyeloablative conditioning regimen and G-CSF-mobilized peripheral blood stem cells, from his HLA-identical brother. Following diagnosis he had received a conventional allogeneic unmanipulated bone marrow transplant in 1st CR and conventional chemotherapy in 1st relapse post transplant, followed by donor lymphocyte infusion (0.93 × 10 8 CD3 positive T lymphocytes/kg) in 2nd CR. At the time of the non-myeloablative conditioning regimen he had been in 2nd relapse for 6 months treated paliatively with vinblastine and steroids. He retained a good performance status, normal physical examination and no evidence of active infection. Both donor and recipient were seropositive for EBV with no serological evidence of viral reactivation. The conditioning regimen consisted of fludarabine, (25 mg/m 2 /day) day Ϫ14 to day Ϫ10 followed by busulfan (2 mg/kg/day) day Ϫ9 and day Ϫ8 and anti-thymocyte globulin (Mérieux, Lyon, France) at a dose of 2.5 mg/kg/day from day Ϫ7 to day Ϫ3. Donor unmanipulated G-CSF-mobilized PBSC were infused on day 0. The graft contained 10.3 × 10 6 CD34 positive cells/kg recipient weight in addition to 1.4 × 10 8 CD19 positive cells/kg and 5 × 10 8 CD3 positive cells/kg. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine 3 mg/kg/day CIVI starting on day Ϫ1. The patient became febrile on day 16 and despite broad-spectrum antibiotics remained febrile until death. The first evidence of active EBV infection was seen on day 30, with positive EBV blood cultures and presence of many enlarged lymph nodes on thoracic and abdominal CT scan. He died on day 32 of multi-organ failure with liver and kidney failure. Post-mortem percutaneous liver and bone marrow biopsies were performed. The liver was massively infiltrated by a polyclonal lymphoproliferative disease with some immunoblast staining with anti-LMP and anti-Zebra monoclonal antibodies. There was no sign of VOD or GVHD. No hematopoietic cells were present in the bone marrow which was infiltrated with immunoblasts, polyclonal activated lymphocytes, plasma cells and macrophages. An EBV cell line of donor origin (as assessed by VNTR analysis) grew spontaneously from the blood of this patient.
Discussion
This patient died from an EBV-associated lymphoproliferative disorder which probably started as early as day 16 after a non-myeloablative unmanipulated HLA-identical peripheral blood stem cell transplant.
Use of anti-CD3 monoclonal antibody for the treatment of acute GVHD and T cell depletion of the donor bone marrow has been shown to be a statistically significant risk factor for this complication, and GVHD appears to play a contributing role.
3 ATG either post-transplant 4 or pre-transplant 5 may have played a role. In the report by Shapiro et al 5 of eight patients who developed BLPD, five had received ATG either pre-and post-transplant (three patients had also had marrow T cell depletion) or only post-transplant as GVHD prophylaxis (two patients with non-T celldepleted bone marrow). Thus, in the large series of posttransplant BLPD, risk factors included T cell depletion and additional post-transplant immunosuppression with anti-T lymphocyte agents. In our experience the only post-transplant immunosuppression was cyclosporine at a conventional dose. At the time the disease developed the cyclosporine level was in the normal therapeutic range (202 g/ml) and it remained at this level until it was stopped on day 27 because of renal insufficiency.
One cannot exclude the possibility that BLPD occurred before the transplant from B cells present in the host who then underwent heavy and prolonged immunosuppression (14 days). The donor origin of the spontaneous EBV cell line grown from the patient's peripheral blood does not rule out this hypothesis since this was the second transplant from the same donor, and residual donor B cells from the first transplant may have persisted in the patient. If this is the case, it raises the question of failure of the second transplant donor T cells to control the BLPD. Indeed, both Papadopoulos et al 6 and Heslop et al 7 have reported cure of post-bone marrow transplant BLPD following administration of up to 10 6 unmanipulated donor-derived CD3 + T cells/kg. Our patient received 500 times more CD3 + T cells harvested from a healthy EBV seropositive donor when the frequency of EBV-specific CTLs in the blood is expected to be high. 8 Whether or not T cells harvested after G-CSF mobilisation in humans have impaired function is not known. However, an unexpected higher frequency of EBVrelated BLPD has not been reported following allogeneic G-CSF-mobilized peripheral blood stem cell transplants after conventional conditioning as compared to bone marrow transplants. Although our patient may have had an EBV mutant lacking the epitopes recognized by virusspecific CTLs as already described, 9 this case raises the question of unexpected drug-induced immunosuppression impairing at least the donor T cell antiviral functions. Since cyclosporine levels remained in the therapeutic range and this is not associated with an increased risk of post-transplant BLPD, this drug can be implicated only if the donor T cells were unusually sensitive to suppression by cyclosporine. Given the pharmacokinetic profile of fludarabine 10 and although we did not perform pharmacokinetic studies in our patient, the risk of the immunosuppressive effects of fludarabine lasting for more than 10 days after the last infusion is negligible. The same cannot be postulated regarding ATG, however, since little if anything is known about its pharmacokinetic profile and whether or not an immunosuppressive effect could persist for days after the last infusion. We report this case because it may emphasize the risk of such non-myeloablative conditioning regimens: impaired donor T cell function increasing the risk of viral complications but also decreasing any GVL effect.
